Olema Pharmaceuticals, Inc. (OLMA)

Compare

3.3300

-0.0100

(-0.30%)

At close: 4:00:01 PM EDT

3.3000

-0.03

(-0.90%)

After hours: 5:02:00 PM EDT

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to 5 new employees to purchase an aggregate of 64,900 shares of the Company's common stock, effective as of April 1, 2025. These awards were approved by the Compensat

GlobeNewswire 1 hour ago

OLMA
-0.30%
Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting

SAN FRANCISCO, March 25, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present a poster highlighting preclinical anti-tumor activity of OP-3136, a novel small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), in prostate, ovarian, and

GlobeNewswire 8 days ago

OLMA
-0.30%
Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L metastatic breast cancer on track for top-line data in 2026Pivotal Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in patients with frontline metastatic breast cancer enabled by new Novartis collaboration and $250 million equity private placement; trial on track for initiation this yearPromising updated results from the ongoing Phase 1b/2 study of palazestrant in combination with ribocicli

GlobeNewswire 15 days ago

OLMA
-0.30%
Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference

SAN FRANCISCO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025 at 10:30 a.m. ET. A live webcast of the pr

GlobeNewswire last month

OLMA
-0.30%
Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary

SAN FRANCISCO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the appointment of Shawnte M. Mitchell, J.D., as Chief Legal Officer and Corporate Secretary. “We are pleased to welcome Shawnte to our executive team to lead our Legal function as we progress both our late

GlobeNewswire last month

OLMA
-0.30%
Olema Oncology to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that management will participate in the following investor conferences: Oppenheimer 35th Annual Healthcare Life Sciences ConferenceDate: Wednesday, February 12, 2025 at 9:20 a.m. ETFormat: Virtual Presentat

GlobeNewswire last month

OLMA
-0.30%
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that Sean P. Bohen, M.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 14, 2025 at 3:45 p.m. PT

GlobeNewswire 2 months ago

OLMA
-0.30%
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability in patients with ER+/HER2- advanced or metastatic breast cancer With a median follow-up of 12 months, median progression-free survival (PFS) has not been reached6-month PFS rate was 73% in all patients, 81% in patients with ESR1 mutations, 70% in ESR1 wild-type patients, and 68% in patients with prior CDK4/6 inhibito

GlobeNewswire 3 months ago

OLMA
-0.30%
Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor

Phase 1 clinical trial for OP-3136 to initiate in early 2025 SAN FRANCISCO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for OP-3136, a novel small molecule t

GlobeNewswire 3 months ago

OLMA
-0.30%
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion

NVS is all set to strengthen its neuroscience pipeline with the addition of PTCT's Huntington's disease drug.

Zacks 3 months ago

NVS

PTCT

OLMA
-0.30%
Novartis and Olema expand alliance with $250m to boost breast cancer trials

Olema Oncology plans to start a Phase III trial studying palazestrant with a CDK4/6 inhibitor from Novartis in mid-2025.

Pharmaceutical Technology 3 months ago

NVS

OLMA
-0.30%
Olema Partners With Novartis for Clinical Trial of Potential Breast Cancer Drug, Launches $250 Million Stock, Warrant Placement

Olema Pharmaceuticals (OLMA) said Monday it has launched a clinical trial collaboration and supply

PREMIUM
MT Newswires 3 months ago

OLMA
-0.30%
NVS
Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement

Clinical trial collaboration and supply agreement enables pivotal Phase 3 OPERA-02 clinical trial of palazestrant in combination with ribociclib in frontline ER+/HER2- metastatic breast cancer; trial initiation expected in mid-2025$250.0 million equity private placement with participation by new and existing investors including Adage Capital Partners LP, Bain Capital Life Sciences, BVF Partners L.P., Driehaus Capital Management, Janus Henderson Investors, Paradigm BioCapital Advisors, Wellington

GlobeNewswire 3 months ago

OLMA
-0.30%
Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

Olema will host an investor conference call at 8:00 a.m. ET on December 10, 2024SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that it will present new data from the Phase 1b/2 clinical study of palazestrant (OP-1250) in combination with CDK4/6 inhibito

GlobeNewswire 4 months ago

OLMA
-0.30%
Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024.

PR Newswire 4 months ago

TLPH

ASPHF

OLMA
-0.30%
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Presented compelling new preclinical data demonstrating anti-tumor activity for OP-3136, a novel KAT6 inhibitor, with enhanced activity of palazestrant combinations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) New clinical data for palazestrant (OP-1250) in combination with ribociclib to be presented at the San Antonio Breast Cancer Symposium (SABCS) in DecemberIND submission for OP-3136 expected before year end; clinical study to initiate early 2025Cash, c

GlobeNewswire 4 months ago

OLMA
-0.30%
Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 4 months ago

OLMA
-0.30%
Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024

OP-3136, a potent KAT6 inhibitor, demonstrated robust anti-tumor activity as a single agent, as well as synergy and enhanced anti-tumor activity in combination with palazestrant; IND submission expected before year endPalazestrant demonstrated combinability and enhanced tumor suppression with both everolimus and capivasertib SAN FRANCISCO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused

GlobeNewswire 5 months ago

OLMA
-0.30%
Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Poster presentations include new preclinical data demonstrating activity for palazestrant in combination with capivasertib and everolimus, and OP-3136, Olema’s KAT6 inhibitor, in combination with palazestrant and other targeted agentsSAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancer

GlobeNewswire 5 months ago

OLMA
-0.30%
Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference

SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that its management team will participate in the following upcoming investor conference: Morgan Stanley 22nd Annual Global Healthcare ConferenceDate: Wednesday, September 4, 2024, at 7:45 a.m. ETLocation: Marriott Mar

GlobeNewswire 7 months ago

OLMA
-0.30%

Performance Overview

Return	OLMA	S&P 500 (^GSPC)
YTD	-42.88%	-3.58%
1-Year	-69.28%	+8.94%
3-Year	-18.78%	+24.75%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Olema Pharmaceuticals, Inc. (OLMA)

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting

Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference

Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary

Olema Oncology to Participate in Upcoming Investor Conferences

Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference

Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor

Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion

Novartis and Olema expand alliance with $250m to boost breast cancer trials

Olema Partners With Novartis for Clinical Trial of Potential Breast Cancer Drug, Launches $250 Million Stock, Warrant Placement

Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement

Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024

Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference

Performance Overview